Insiders Trades
BH
Bachem Holding AG Stock: price and insider trades · Switzerland
No insider purchase over the last 90 days. The latest was filed 16 Mar 2026.
Bachem Holding AG: what insiders have been doing
Bachem Holding AG belongs to the Healthcare & Pharma sector. Filings by its managers are published through SIX SER. In the past year (18 October 2025 to 18 October 2026), 3 filings came from 3 insiders.
Open-market activity splits into 1 purchase totalling €17k and 2 sales totalling €243k; 1 insider sit on the buying side and 2 insiders on the selling side. Sales outweigh purchases by €226k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The filings include the largest sale, €121k, on 8 May 2026. The buyers include 1 senior executive.
Across the 178 companies tracked on its exchange, the median is 9 filings; at 3 filings, this issuer sits below that mark. The full history, which starts in 2023, counts 2 purchases against 6 sales.
The last purchase on record was published on 16 March 2026, which is 216 days ago. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SIX SER. Past trades are no guide to future returns.
Insider Decl.
8
Thresholds
n/a
Buy Volume
€49,106
2 ops. · all time
Sell Volume
€660,757
6 ops. · all time
Who traded when
BuySaleAnonymous (Executive member of the board of directors / member of senior management)4 sales
Anonymous (Non-executive member of the board of directors)2 buys
Anonymous (an executive member of the board of directors / member of senior management)1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 8 May 2026
Declarations8 total
▼
Anonymous (an executive member of the board of directors / member of senior management)
1,373 shares@ CHF 81.02100.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q58000D2
▼
Anonymous (Executive member of the board of directors / member of senior management)
1,373 shares@ CHF 81.01530.8% of flowISIN CH1176493729SIX:T1Q58000D2
248 shares@ CHF 61.008.7% of flowISIN CH1176493729SIX:T1Q3G000I1
Canonical exit: 14 Jun 2026 (T+90)
▼
Anonymous (Executive member of the board of directors / member of senior management)
1,000 shares@ CHF 56.5015.4% of flowISIN CH1176493729SIX:T1PAF000A9
▼
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 56.4038.5% of flowISIN CH1176493729SIX:T1PAF00082
▼
Anonymous (Executive member of the board of directors / member of senior management)
1,000 shares@ CHF 56.27715.4% of flowISIN CH1176493729SIX:T1PAF00090
595 shares@ CHF 50.9516.7% of flowISIN CH1176493729SIX:T1P5600095
Canonical exit: 4 Aug 2025 (T+90)
2,200 shares@ CHF 62.0074.6% of flowISIN CH0012530207SIX:T1NCK00042
8 of 8 declarations
About Bachem Holding AG
Bachem Holding AG is a Swiss specialty chemicals and CDMO group focused on the development and manufacturing of peptides and oligonucleotides, two highly complex molecule classes that are increasingly important in next-generation therapeutics. The company is listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland under the ticker BANB, and it serves a global client base of pharmaceutical and biotechnology companies that outsource critical parts of the value chain, from early-stage development through to reliable commercial supply. Bachem was founded in 1971 by Peter Grogg in Liestal and later relocated to Bubendorf, where its headquarters and largest GMP manufacturing hub are now located. From its origins as a peptide synthesis laboratory, the company has grown into a global reference in TIDES manufacturing, with industrial and commercial operations across Europe, the United States and Asia.
Its business model rests on two core pillars: clinical development and commercial production. Bachem supports customers across the full product lifecycle, including process development, analytical support, scale-up, quality control and GMP manufacturing. Its key offerings include peptide active pharmaceutical ingredients, therapeutic oligonucleotides and related intermediates, with exposure to innovative medicines in areas such as oncology, metabolic disease, rare diseases and targeted therapies.
Read moreShow less
From a competitive standpoint, Bachem holds a strong position thanks to its scientific depth, long-standing peptide expertise and specialized industrial footprint. The group is widely regarded as one of the global leaders in its niche, supported by a reputation for technical reliability and long-term partnerships with major pharmaceutical customers. Its strategic priority is to expand manufacturing capacity in order to capture rising global demand for complex molecule therapeutics.
Recent developments reinforce this growth narrative. In 2025, Bachem continued its capacity expansion program, notably at Bubendorf through Building K, and in the United States at Vista, California, where it acquired adjacent land for future expansion. The company also announced a long-term cooperation agreement for peptide development and supply. In its 2025 financial year results published in March 2026, Bachem reported sales growth and continued high EBITDA profitability, while proposing a higher dividend, underscoring a combination of growth, operational discipline and cash generation. For international investors, Bachem offers structurally attractive exposure to innovative healthcare, backed by a high-quality Swiss industrial base and a truly global operating platform.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
